These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 19147564)

  • 1. Identification of nuclear export inhibitors with potent anticancer activity in vivo.
    Mutka SC; Yang WQ; Dong SD; Ward SL; Craig DA; Timmermans PB; Murli S
    Cancer Res; 2009 Jan; 69(2):510-7. PubMed ID: 19147564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear entrapment of p33ING1b by inhibition of exportin-1: A trigger of apoptosis in head and neck squamous cell cancer.
    Özdaş S
    Cell Mol Biol (Noisy-le-grand); 2018 Apr; 64(5):66-72. PubMed ID: 29729696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ratjadone and leptomycin B block CRM1-dependent nuclear export by identical mechanisms.
    Meissner T; Krause E; Vinkemeier U
    FEBS Lett; 2004 Oct; 576(1-2):27-30. PubMed ID: 15474004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leptomycin B alters the subcellular distribution of CRM1 (Exportin 1).
    Rahmani K; Dean DA
    Biochem Biophys Res Commun; 2017 Jun; 488(2):253-258. PubMed ID: 28412356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds.
    Crochiere ML; Baloglu E; Klebanov B; Donovan S; Del Alamo D; Lee M; Kauffman M; Shacham S; Landesman Y
    Oncotarget; 2016 Jan; 7(2):1863-77. PubMed ID: 26654943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel reversible selective inhibitor of nuclear export shows that CRM1 is a target in colorectal cancer cells.
    Niu M; Chong Y; Han Y; Liu X
    Cancer Biol Ther; 2015; 16(7):1110-8. PubMed ID: 25996664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel small molecule XPO1/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells.
    Yang J; Bill MA; Young GS; La Perle K; Landesman Y; Shacham S; Kauffman M; Senapedis W; Kashyap T; Saint-Martin JR; Kendra K; Lesinski GB
    PLoS One; 2014; 9(7):e102983. PubMed ID: 25057921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity.
    Sakakibara K; Saito N; Sato T; Suzuki A; Hasegawa Y; Friedman JM; Kufe DW; Vonhoff DD; Iwami T; Kawabe T
    Blood; 2011 Oct; 118(14):3922-31. PubMed ID: 21841164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.
    Kashyap T; Argueta C; Aboukameel A; Unger TJ; Klebanov B; Mohammad RM; Muqbil I; Azmi AS; Drolen C; Senapedis W; Lee M; Kauffman M; Shacham S; Landesman Y
    Oncotarget; 2016 Nov; 7(48):78883-78895. PubMed ID: 27713151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of CRM1 activity sensitizes endometrial and ovarian cell lines to TRAIL-induced cell death.
    Fabi F; Adam P; Vincent K; Demontigny F; Parent S; Joncas FH; Asselin E
    Cell Commun Signal; 2018 Jul; 16(1):39. PubMed ID: 29973205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia.
    Ranganathan P; Yu X; Na C; Santhanam R; Shacham S; Kauffman M; Walker A; Klisovic R; Blum W; Caligiuri M; Croce CM; Marcucci G; Garzon R
    Blood; 2012 Aug; 120(9):1765-73. PubMed ID: 22677130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leptomycin B inhibition of signal-mediated nuclear export by direct binding to CRM1.
    Kudo N; Wolff B; Sekimoto T; Schreiner EP; Yoneda Y; Yanagida M; Horinouchi S; Yoshida M
    Exp Cell Res; 1998 Aug; 242(2):540-7. PubMed ID: 9683540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nucleocytoplasmic shuttling and the biological activity of mouse survivin are regulated by an active nuclear export signal.
    Stauber RH; Rabenhorst U; Rekik A; Engels K; Bier C; Knauer SK
    Traffic; 2006 Nov; 7(11):1461-72. PubMed ID: 16984408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents.
    Turner JG; Dawson J; Cubitt CL; Baz R; Sullivan DM
    Semin Cancer Biol; 2014 Aug; 27():62-73. PubMed ID: 24631834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear export of proteins and drug resistance in cancer.
    Turner JG; Dawson J; Sullivan DM
    Biochem Pharmacol; 2012 Apr; 83(8):1021-32. PubMed ID: 22209898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRM1 protein-mediated regulation of nuclear clusterin (nCLU), an ionizing radiation-stimulated, Bax-dependent pro-death factor.
    Leskov KS; Araki S; Lavik JP; Gomez JA; Gama V; Gonos ES; Trougakos IP; Matsuyama S; Boothman DA
    J Biol Chem; 2011 Nov; 286(46):40083-90. PubMed ID: 21953454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells.
    Etchin J; Sun Q; Kentsis A; Farmer A; Zhang ZC; Sanda T; Mansour MR; Barcelo C; McCauley D; Kauffman M; Shacham S; Christie AL; Kung AL; Rodig SJ; Chook YM; Look AT
    Leukemia; 2013 Jan; 27(1):66-74. PubMed ID: 22847027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma.
    Zheng Y; Gery S; Sun H; Shacham S; Kauffman M; Koeffler HP
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):487-95. PubMed ID: 25030088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRAIL responses are enhanced by nuclear export inhibition in osteosarcoma.
    Phillips KL; Wright N; McDermott E; Cross NA
    Biochem Biophys Res Commun; 2019 Sep; 517(2):383-389. PubMed ID: 31362889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.
    Etchin J; Sanda T; Mansour MR; Kentsis A; Montero J; Le BT; Christie AL; McCauley D; Rodig SJ; Kauffman M; Shacham S; Stone R; Letai A; Kung AL; Thomas Look A
    Br J Haematol; 2013 Apr; 161(1):117-27. PubMed ID: 23373539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.